Company news

ImmuneOnco won the project supported by Science and Technology Commission of Shanghai Municipality.

2017-6-7 0:00:00Click:476

 On May 6, 2017, ImmuneOnco Biopharmaceuticals Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, announced that,one of its research projects won the supportion by Shanghai science and technology achievements transformation and industrialization project; the project No.: 17431905500. The project is a preclinical study of a novel immunomodulatory target, the anti-tumor recombinant protein drug rhSIRPaD1-Fc.

 “The functional protein targeting CD47 is one of many exciting programs in our preclinical development portfolio," said Dr. Wenzhi Tian, Chairman and Chief Executive Officer of ImmuneOnco. "  We plan to file the IND of our novel functional protein as early as early 2018."

 The project is the activation of macrophages by blocking the interaction of CD47-SIRPa, which play on phagocytosis of tumor cells, tumor antigen and phagocytosis treatment presented to T cells, which play a strong effect of tumor immunotherapy. Preclinical studies prove that, while blocking CD47 and SIRPa signals, significantly therapeutic effect in several tumor models.

 Patent application number in China: 201510203619.7, the title: a new recombinant bifunctional fusion protein and its preparation and application;the inventor: ImmuneOnco Biopharmaceuticals Co., Ltd.